# A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

> **NCT07024173** · PHASE3 · RECRUITING · sponsor: **Shandong Suncadia Medicine Co., Ltd.** · enrollment: 240 (estimated)

## Conditions studied

- Locally Advanced Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** HRS-8080 Tablet
- **DRUG:** Fulvestrant injection
- **DRUG:** Exemestane tablets
- **DRUG:** Everolimus Tablets
- **DRUG:** Anastrozole Tablets
- **DRUG:** Letrozole Tablets

## Key facts

- **NCT ID:** NCT07024173
- **Lead sponsor:** Shandong Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-23
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07024173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07024173, "A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07024173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*